Company news: Edelman, Pfizer, Publicis, Lippincott

Share this article:

Dan Edelman, founder of the eponymous PR firm, a major player in healthcare PR, has died. The former reporter founded his agency in Chicago 61 years ago, reported PRWeek. He is survived by his wife, Ruth, a daughter, Renee, sons Richard and John and granddaughters Margot, Tory, and Amanda.

Pfizer's Geno Germano, head of specialty and oncology, told Bloomberg that Pfizer would "probably evolve to two" divisions, fueling speculation that the firm might follow Abbott Labs' lead and split. Spokeswoman Joan Campion dismissed the report as speculation spiked with dated comments from analysts. “There is no new news here,” she told MM&M, noting that the idea of breaking up the company surfaces every quarter, and adding that nothing in the business structure has changed. Germano was quoted as saying the company will probably “evolve to two, where there's the innovative business and the value business.” Pfizer offloaded its nutrition business on Nestle in early 2012, and is expected to spin off its animal business under the name Zoetis this year.

Industry vet Mark Stevens has been hired on as SVP, commercial solutions for Publicis Touchpoint Solutions. Stevens, who has held posts with Wolters Kluwer, Bristol-Myers Squibb, Pfizer and Sanofi, will be in charge of enhancing customer-directed tech and tools.

Lippincott's latest Nursing Advisor includes a pill identifier and drug interactions tool that can help nurses troubleshoot patient medications. The tool means nurses will be able to identify what a patient is taking by entering variables such as a pill's color, shape, score or dose. Nurses will also be able to cross-reference medications with multiple drugs, patient allergies, patient gender and diseases, among other factors.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.